Trial Profile
Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Poly ICLC (Primary) ; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacogenomic
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Jan 2015 Status changed from not yet recruiting to completed according to ClinicalTrials.gov record.
- 27 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2015 s reported by ClinicalTrials.gov record.